Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
Nurix Therapeutics Shares Plunge 28.4% as Sanofi Terminates STAT6 Drug Development Programme
Wells Fargo Maintains Equal-Weight on Nurix Therapeutics, Lowers Price Target to $20
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
Nurix Therapeutics stock tumbles on Sanofi program termination
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Nurix Therapeutics Announces That Sanofi Notified Co. Of Its Decision To Discontinue The Phase 1 First-In-Human Clinical Trial Of SAR448272, And To Terminate The SAR448272 Program
What Nurix Therapeutics Stock's Profit Turnaround Means For Shareholders
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32
Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.